Hormonal agents (2)
Sigma Aldrich (2)
TCI Chemicals (2)
Melatonin (8041-44-9, 73-31-4)
Melatonin, also known as N-acetyl-5-methoxy tryptamine, is a hormone that is produced by the pineal gland in animals and regulates sleep and wakefulness. Melatonin is also produced in plants where it functions as a first line of defense against oxidative stress. In animals, melatonin is involved in the entrainment (synchronization) of the circadian rhythms including sleep-wake timing, blood pressure regulation, seasonal reproduction, and many others.
Camptothecin (CPT) is a topoisomerase inhibitor. It was discovered in 1966 by M. E.
Swainsonine is an indolizidine alkaloid. It is a potent inhibitor of Golgi alpha-mannosidase II, an immunomodulator, and a potential chemotherapy drug. As a toxin in locoweed (likely its primary toxin) it also is a significant cause of economic losses in livestock industries, particularly in North America.
berberine (2086-83-1, 4263-84-7)
Berberine is a quaternary ammonium salt from the protoberberine group of benzylisoquinoline alkaloids found in such plants as Berberis (e.g. Berberis vulgaris - barberry, Berberis aristata - tree turmeric, Mahonia aquifolium - Oregon-grape, Hydrastis canadensis - goldenseal, Xanthorhiza simplicissima - yellowroot, Phellodendron amurense - Amur cork tree, Coptis chinensis - Chinese goldthread, Tinospora cordifolia, Argemone mexicana - prickly poppy, and Eschscholzia californica - Californian poppy. Berberine is usually found in the roots, rhizomes, stems, and bark.
Vinflunine (INN, trade name Javlor) is a novel fluorinated vinca alkaloid derivative undergoing research for the treatment of bladder cancer. It was originally discovered by the team of the Professor Jean-Claude Jacquesy (UMR CNRS 6514 - Poitiers University), developed by Laboratoires Pierre Fabre and was licensed to Bristol-Myers Squibb for development in certain countries, including the United States. On November 23, 2007, Pierre Fabre Medicament and Bristol-Myers Squibb announced that they were terminating their license agreement for the development of vinflunine, and that Pierre Fabre were continuing "discussions with regulatory authorities and plan to file for the registration of vinflunine for bladder cancer in the first quarter of 2008." As of 2016, vinflunine is the only commercially-approved agent in some countries for salvage therapy of urothelial carcinoma, (with approval based on the results of a phase III trial), with a reported median OS of about 6 months.